sofosbuvir and daclatasvir for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID-19 severe or critically meta-analysis
Eslami IRCT20200324046850N2		NRa	sofosbuvir and daclatasvir	ribavirin	COVID-19 severe or critically	NA	35/27	uncontrolled	[uncontrolled] deaths: 5.7% (2/35) [uncontrolled] recovery rate: 94.3% (33/35)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID-19 severe or critically meta-analysis